Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Zhuoyan Li, MD, Samuel M Rubinstein, MD, Carey Clifton, ACNP, Leigh Ann Vaughan, ACNP, Melissa Logue, ACNP, Michael T. Byrne, DO, Adetola A. Kassim, MD MS, Brian G Engelhardt, MD, Wichai Chinratanalab, MD, Salyka Sengsayadeth, MD, Stephen J. Brandt, MD, Stacey A. Goodman, MD MS, John P. Greer, MD, Madan Jagasia, MD, Bipin N. Savani, MD

Blood (2016) 128 (22): 3438.

https://doi.org/10.1182/blood.V128.22.3438.3438

Published: 2016

Journal Articles

"Osteonecrosis of Jaw (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma (MM) : Monocentric Experience of Decreasing ONJ Incidence after Preventive Measures."

Gioacchino Catania, Federico Monaco, MD, Marco Ladetto, MD, Paola Pepe, Jr., Giulia Limberti, Manuela Alessio, Anna Baraldi, MD, Antonella Fasciolo, Vittorio Fusco

Blood (2016) 128 (22): 5917.

https://doi.org/10.1182/blood.V128.22.5917.5917

Published: 2016

Journal Articles

A Systematic Review of the Classification, Diagnosis, Treatment and Outcome of Osteonecrosis of the Hips in Sickle Cell Disease

Dalal Hamza Mulla-Ali, BCh, BAO, LRCPSI, FRCPC, Kevin H.M. Kuo, MD MSc, FRCPC, Ambica Parmar, MD, Yves D. Pastore, MD

Blood (2015) 126 (23): 2069.

https://doi.org/10.1182/blood.V126.23.2069.2069

Published: 2015

Journal Articles

Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data

Yi Qian, PhD, Debajyoti Bhowmik, B.Pharm, PhD, Nandita Kachru, MS, Rohini K. Hernandez, PhD, Paul Cheng, MD PhD, Alexander Liede, BSc, MSc, PhD

Blood (2015) 126 (23): 4501.

https://doi.org/10.1182/blood.V126.23.4501.4501

Published: 2015

Journal Articles

Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy

Pelagia Melea, Tina Bagratuni, Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Ioannis Melakopoulos, Efstathios Kastritis, MD, Meletios A. Dimopoulos

Blood (2014) 124 (21): 2115.

https://doi.org/10.1182/blood.V124.21.2115.2115

Published: 2014

Journal Articles

Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Aurélie Jaspers, MD, Frederic Baron, MD PhD, Johan Maertens, MD PhD, Bernard J. M. De Prijck, MD, Henri (Rik) Schots, MDPhD, Christophe Bonnet, MD PhD, Kaoutar Hafraoui, MD, Evelyne Willems, MD PhD, Sophie Servais, MD PhD, Georges Fillet, MD PhD, Yves Beguin, MD PhD

Blood (2014) 124 (21): 3948.

https://doi.org/10.1182/blood.V124.21.3948.3948

Published: 2014

Journal Articles

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Rasim Gucalp, MD, Karl Insogna, MD, Mimi Hu, MD, Ilya Glezerman, MD, Sophie Leboulleux, MD, Waldemar Misiorowski, MD, Bennett Yu, MD, Paul Zorsky, MD, Diego Tosi, MD, Alberto Bessudo, MD, Arnaud Jaccard, MD, Giuseppe Tonini, MD, Wendy Ying, PhD, Ada H. Braun, MD, PhD, Rajul K. Jain, MD

Blood (2013) 122 (21): 2536.

https://doi.org/10.1182/blood.V122.21.2536.2536

Published: 2013

Journal Articles

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Efstathios Kastritis, Evangelos Terpos, Ioannis Melakopoulos, Pelagia Melea, Despoina Kalapanida, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Marina Iakovaki, Dimitrios Christoulas, Dimitra Gika, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3196.

https://doi.org/10.1182/blood.V122.21.3196.3196

Published: 2013

Journal Articles

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Ashraf Badros, MD, Sunita Philip, Patricia Lesho, Mariola Sadowska, Dianna Weikel, Timothy Meiller, Rena Lapidus, Lisa Hester, Todd Milliron, Olga Goloubeva

Blood (2013) 122 (21): 3153.

https://doi.org/10.1182/blood.V122.21.3153.3153

Published: 2013

Journal Articles

Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Parameswaran Hari, MBBS, MD, MRCP, Todd E. Defor, MS, David H. Vesole, MD, PhD, Christopher Bredeson, MD, MSc, FRCPC, Linda J Burns, MD

Blood (2012) 120 (21): 1965.

https://doi.org/10.1182/blood.V120.21.1965.1965

Published: 2012

Journal Articles

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Chirayu Patel, Andrew Yee, Tyler A. Scullen, Neeharika Nemani, Loredana Santo, Anuj Mahindra, Paul G. Richardson, MD, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Robert Schlossman, MD, Kenneth C. Anderson, Nikhil C Munshi, MD, Noopur Raje

Blood (2012) 120 (21): 3965.

https://doi.org/10.1182/blood.V120.21.3965.3965

Published: 2012

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

Journal Articles

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Ashraf Z. Badros, MD, Sunita Philip, Patricia Lesho, Dianna Weikel, Olga Goloubeva, Mariola Sadowska, Rena Lapidus, PhD, Lisa Hester, Todd Milliron, Timothy Meiller

Blood (2012) 120 (21): 4245.

https://doi.org/10.1182/blood.V120.21.4245.4245

Published: 2012

Journal Articles

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Albrecht Reichle, Christina Hart, Matthias Grube, Reinhard Andreesen

Blood (2012) 120 (21): 5029.

https://doi.org/10.1182/blood.V120.21.5029.5029

Published: 2012

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Noopur Raje, MD, Robert Vescio, MD, Charles W. Montgomery, MD, Ramakrishnan Parameswaran, MD, Diep Tran, MS, Ghulam Warsi, PhD, Eliza Argonza-Aviles, RN, MSHS, Solveig G. Ericson, MD- PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 5122.

https://doi.org/10.1182/blood.V118.21.5122.5122

Published: 2011

Journal Articles

Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bispohosphonates

Samantha Pozzi, MD, Raffaella Marcheselli, MS, Alessia Bari, MD, Eliana Valentina Liardo, MD, Paola Bresciani, MD, Maria Teresa Donini, MD, Santo Neri, MD, Luciano Masini, Giuseppe Caparrotti, MD, Pellegrino Musto, Elisa Ferraris, MD, Daniela Petro, MD, Luigi Marcheselli, MS, Antonio Palumbo, MD, Stefano Sacchi, MD

Blood (2011) 118 (21): 5134.

https://doi.org/10.1182/blood.V118.21.5134.5134

Published: 2011

Journal Articles

Cost-Effectiveness of Zoledronic Acid Versus Clodronate In Patients with Multiple Myeloma From a Canadian Healthcare System Perspective.

Thomas E. Delea, M.S.I.A., Khalid El Ougari, PhD, Jason Rotter, BA, Alice Wang, MA, Satyin Kaura, MEng, MBA, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 3812.

https://doi.org/10.1182/blood.V116.21.3812.3812

Published: 2010

Journal Articles

Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ.

Prakash Varadarajan, MD, Juan Toro, Robert M. Craig, Deanna Schneider, Ju-Hsien Chao, David Haile, Cesar O. Freytes, MD

Blood (2010) 116 (21): 1314.

https://doi.org/10.1182/blood.V116.21.1314.1314

Published: 2010

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Blood (2010) 116 (21): 2971.

https://doi.org/10.1182/blood.V116.21.2971.2971

Published: 2010

NARROW

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

"Osteonecrosis of Jaw (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma (MM) : Monocentric Experience of Decreasing ONJ Incidence after Preventive Measures."

A Systematic Review of the Classification, Diagnosis, Treatment and Outcome of Osteonecrosis of the Hips in Sickle Cell Disease

Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data

Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy

Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bispohosphonates

Cost-Effectiveness of Zoledronic Acid Versus Clodronate In Patients with Multiple Myeloma From a Canadian Healthcare System Perspective.

Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ.

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only